The little insecure dweeb Werner must have bought the stock much higher. He calls OMER garbage after a 100%+ run this year alone. Only people who bash a stock this much have bought higher. I wouldnt doubt he bought it at the years high.....or he is a short with his girlfriend art doyle.
In 2025 I will post to this board telling the story how I multiplied my Investment by 50x and how not to miss a one time life opportunity when you find it. Again, under $1B market cap with Omidria that's on the target to fund the whole pipeline this is the most derisked biotech on the market now, period 💰 💰💰 💰
Long and strong OMER. Shorts over 9 mil and earnings will beat. Going to mute all of the idiots here like wiener54739 and watch this baby double by year end.
Dr.G doesn't care about the day to day price movement and he is not going to hype the company. He knows we are a winner, If you guys keep looking a the price by the hour, your nuts
good lord what is going on
A rare gem
Cory Renauer (Omeros Corporation): This biotech has a rare disease drug in development that could render its stock chart into the shape of a hockey stick. The candidate, tentatively named OMS721, throws a wrench in the works of a complex series of steps that can lead to the uncontrolled destruction of tiny blood vessels. The normal function of this component of the immune system removes foreign particles. Among a small group of patients with rare genetic conditions, though, uncontrolled activation of the complement system leads to life threatening clots within tiny blood vessels throughout the body. There is a treatment available for one of these genetic conditions, atypical hemolytic uremic syndrome (aHUS), called Soliris from Alexion Pharmaceuticals. Unfortunately for aHUS patients it often causes headaches, diarrhea, and has been known to increase the risk of dangerous infections. Despite Soliris' drawbacks, it raked in a stunning $2.6 billion last year, and it stands to reason that a more tolerable treatment for inherited complement system disorders could top this figure.
Omeros Corporation's stock price has more than doubled this year, as the company dropped hints an ongoing clinical trial with aHUS patients designed to support an FDA application could succeed. A relative lack of side effects compared to Soliris could make a potential new drug launch incredibly successful, provided it earns FDA approval. If OMS721 becomes half as successful as Soliris, this company's market cap of just $965 million would probably swell to several times its current size. Perhaps my favorite feature of this biotech is that it already has a growing source of revenue to fund OMS721's clinical trials. The company markets a pupil dilator called Omidria, and it's becoming increasingly popular among eye surgeons that perform millions of cataract removals and lens replacement surgeries each year. Omidria's ability to reduce complications has sent its sales surging to a level could make Omeros a profitable company this year, which could limit losses if an unexpected snafu causes OMS721 to fizzle.
Looks like they are trying to get their clinical trial stuff together. Position was posted on 7/18 (also just fyi that omer has total of 2new openings which is a great indicator of growth).
Clinical Trial Manager/Senior Manager
As a member of the Clinical Development Team, you’ll work closely with internal team members and vendors as well as clinical study sites ensuring that clinical trials are conducted in a timely fashion and in a manner compliant with SOPs, ICH/GCP/regulatory guidelines, company goals and budgets. You’ll have responsibility for managing the operational aspects of clinical trials including managing clinical operations personnel.
This volume is ridiculous
just playing games in 2 minutes 2500 shares traded and pps dropped 28 cents, comical and no interest.
Report: MASP-2 (target for OMS7221) associated with ischemic stroke and contribution to post-stroke brain damage:
J Clin Pathol. 2017 Jul 18. pii: jclinpath-2017-204403. doi: 10.1136/jclinpath-2017-204403. [Epub ahead of print] Serine proteases of the complement lectin pathway and their genetic variations in ischaemic stroke. Tsakanova G1, Stepanyan A1, Nahapetyan K2, Sim RB3,4, Arakelyan A1, Boyajyan A1. Author information
Abstract AIMS: The aim of the current study was to assess the proteolytic activities of collectin-bound MASP-1 and MASP-2 in the blood of patients with ischaemic stroke, as well as the association of their six genetic polymorphisms (rs3203210, rs28945070, rs28945073 in MASP1 gene and rs2273343, rs12711521, rs147270785 in MASP2 gene) with this pathology. METHODS: In total, 250 patients and 300 healthy subjects were involved in this study. MBL-associated serine protease (MASP)-1 and MASP-2 activities were measured using in-house developed immunofluorescent and enzyme-linked immunosorbent assays, respectively. Sequence specific primer PCR was used to study the association of MASP1 and MASP2 genetic polymorphisms with ischaemic stroke. RESULTS: The results obtained demonstrate that the activities of collectin-bound MASP-1 and MASP-2 in patients with ischaemic stroke are significantly higher than those in healthy subjects (p<0.001). According to the data obtained for genotyping, the rs3203210 polymorphism in the MASP1 gene and the rs147270785 polymorphism in the MASP2 gene are associated with ischaemic stroke (p<0.0001). CONCLUSIONS: In conclusion we suggest that the complement lectin pathway serine proteases, MASP-1 and MASP-2, can be associated with ischaemic stroke development risk and may participate in pathological events leading to post-ischaemic brain damage. Moreover rs3203210 and rs147270785 single nucleotide polymorphisms in the MASP1 and MASP2 genes, respectively, are strongly associated with ischaemic stroke, and the minor rs3203210*C and rs147270785*A alleles of these polymorphisms may be considered as protective factors for ischameic stroke, at least in the Armenian population.
This means nothing. Bought alittle more this morning. This stock is a winner.
We are getting close now to the EU announcement. Just based on the cash portion of the deal it values the company at $5.0billion or around $110 per share. The quarter will be better than expected as there was a catch on revenues based on improper wholesaling issues. 721 is getting closer at the FDA but not quite there. Before the end of Sept. And believe it or not there is another drug that is anti addition that has huge potential that is being moved along very fast. I will be hard to put a value on all of this. The short story is over with the last failed attempt. No buyout just massive sales, and partnerships.
Good numbers by ALXN bodes well for future sales of OMER!
All the cheerleaders? Where are you now?
Less than 3 weeks until Q2 CC.
Dropped 10% in 2 days on a little over a million shares.
FDA has its orders...approve everything, we own shares. Tom Price March 2, 2017
Wow , talk about no volume! Vacation time, but two weeks to the 2nd Qtr. C.C. Let's hope for some NEWS!
What seems to be the problem?
Added some @ 21.27. Looks to be heading higher after a low volume drift lower...........Kel